Appili Therapeutics Announces Additional Bridge Loan From Bloom Burton & Co.
Aditxt Signs Agreement to Acquire Appili Therapeutics
Appili Therapeutics Reports Q3 Results
Appili Therapeutics Says Patent Issued For Biodefence Vaccine Candidate ATI-1701, Provides Update on Bridge Loan
Appili Therapeutics Inc. (APLI.TO) on Friday said the United States Patent and Trademark Office (USPTO) has published patent claims for ATI-1701. The patent covers the composition and preparation methods for the vaccine through 2039.
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ (ATI-1501) Metronidazole Oral Suspension
FDA approves LIKMEZ as the brand name for Metronidazole Oral Suspension (LIKMEZ is a Trademark of Saptalis Pharmaceuticals, LLC) Currently LIKMEZ is the only liquid oral suspension of metronidazole approved in the
Appili Therapeutics GAAP EPS of -C$0.01
Press Release: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.
Appili Therapeutics – Press Release Correction
Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), announced today a correction to its press release entitled "Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results"
Appili Therapeutics Net Loss of $0.08 Per Share For FY 2023
Appili Therapeutics Inc. (APL.TO), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, on Friday announced its financial and operational results for the fiscal year ended March 31, 2023.
Appili Therapeutics GAAP EPS of -C$0.08
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
Upcoming PDUFA date of September 23, 2023 Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense,
Appili Therapeutics Secures Contract for ATI-1701 Funding From U.S. Air Force Academy
Appili Therapeutics Inc. (APLI.TO), focused on drug development for infectious diseases and biodefense, on Monday said it has executed the initial contract with the U.S. Air Force Academy (USAFA) for the previously announced funding of the ATI-1701 program.
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
Accomplished biopharmaceutical executive brings more than 25 years of experience leading vaccine and antibody product development for infectious disease indications Dr. Nabors representing Appili at the World Vaccine
Appili Therapeutics Inc. Expected to Post FY2023 Earnings of ($0.08) Per Share (TSE:APL)
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Analysts at Zacks Small Cap increased their FY2023 earnings per share (EPS) estimates for shares of Appili Therapeutics in a research note issued to
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to Support the ATI-1701 Biodefense Vaccine Program
Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program. Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF)
Appili to Get US Patent for Antibiotic ATI-1501
Appili Therapeutics Announces Notice of Allowance From the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
Anticipated new patent strengthens ATI-1501's potential position as a more convenient alternative treatment option for metronidazole prescriptions on the market. Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~$14M of Funding
Appili Therapeutics GAAP EPS of -C$0.04
Appili Therapeutics Inc. (TSE:APL) to Post FY2023 Earnings of ($0.09) Per Share, Zacks Small Cap Forecasts
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Equities researchers at Zacks Small Cap boosted their FY2023 earnings estimates for shares of Appili Therapeutics in a note issued to investors on
No Data